valcyte治疗CMV视网膜炎有效果吗？

Is it effective to treat CMV retinitis? Let us take a look below. Valcyte tablets are an oral anti-cytomegalovirus infection drug that combines the advantages of oral administration and intravenous injection. It can effectively prevent and treat cytomegalovirus infection through correct oral administration every day, significantly improving the patient's quality of life and long-term survival rate.

Clinical studies of valcyte tablets in AIDS patients infected with CMV retinitis have shown that valcyte tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the valcyte tablet group or the intravenous valcyte group for induction therapy. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy with 900 mg of valcyte tablets per day. Among patients who received valcyte tablets or intravenous valcyte induction therapy followed by maintenance treatment with valcyte tablets, the mean (median) time from randomization to progression of CMV retinitis was: 226 (160) days and 219 (125) days.

The recommended dose of valcyte for the treatment of induction of cytomegalovirus retinitis is 900 mg (two 450 mg tablets) twice daily for 21 days. Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily.

Cytomegalovirus prophylaxis: For adult patients who have received a heart or kidney-pancreas transplant, the recommended dose is 900 mg orally once daily starting within 10 days of transplantation and continuing until 100 days after transplantation.

The antiviral effect of valcyte tablets has been clinically demonstrated in the treatment of AIDS patients with newly diagnosed retinitis (clinical study WV15376). The detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55) after 4 weeks of treatment.